Newsroom
Top Results
Sight Sciences Announces Positive Interim Clinical Results from Prospective, Multicenter Trial of the OMNI Surgical System in Open Angle Glaucoma
Data presented at the Women in Ophthalmology 2020 Virtual Summer Symposium
Sight Sciences Announces First Patients Enrolled in ORION: A Prospective, Multicenter Clinical Trial of the OMNI Surgical System in Pseudophakic, Mild-to-Moderate Glaucoma Patients
Trial to Provide Surgeons with Prospective, Standalone Clinical Data on Microinvasive Glaucoma Surgery
Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors
Highly accomplished industry executive brings financial and operational expertise to innovative eye care company
Sight Sciences Introduces the Next-Generation OMNI® Surgical System for Microinvasive Glaucoma Surgery
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the launch of its next-generation OMNI Surgical System for microinvasive glaucoma surgery (MIGS) procedures.
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires
Industry veterans will lead scaling of company operations and processes to support OMNI Surgical System and TearCare growth
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology
MENLO PARK, Calif., March 30, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D., has been published in Current Opinion in Ophthalmology.
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners
MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and […]
Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that positive outcomes from a new multicenter study of one of the OMNI® Surgical System’s predecessor devices, TRAB®360, were published in the American Journal of Ophthalmology. Following a 2019 publication1 of a […]